Where Will Imara Inc (IMRA) Stock Go Next After It Is Up 3.69% in a Week?

Friday, October 21, 2022 01:45 PM | InvestorsObserver Analysts

Mentioned in this article

Where Will Imara Inc (IMRA) Stock Go Next After It Is Up 3.69% in a Week?

Imara Inc (IMRA) stock has risen 3.69% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Imara Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on IMRA!

See Full IMRA Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With IMRA Stock Today?

Imara Inc (IMRA) stock is down -7.58% while the S&P 500 is up 1.67% as of 1:43 PM on Friday, Oct 21. IMRA has fallen -$0.32 from the previous closing price of $4.25 on volume of 228,780 shares. Over the past year the S&P 500 is lower by -17.84% while IMRA is up 8.26%. IMRA lost -$2.08 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Imara Inc click here.

More About Imara Inc

Imara Inc is a clinical-stage biopharmaceutical company engaged in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Its lead product candidate, tovinontrine (IMR-687), is an oral, highly selective, potent small-molecule inhibitor of phosphodiesterase-9, or PDE9. Click Here to get the full Stock Report for Imara Inc stock.